Start Date
December 31, 2017
Primary Completion Date
January 31, 2018
Study Completion Date
January 31, 2018
RPH001
Avastin® has been approved for treatment of various cancers in many countries of the world including the USA, EU countries, and Turkey. In Turkey, Avastin® is approved with a different trade name, Altuzan®, for treatment of metastatic colorectal cancer.
Avastin®
R-Pharm created a biological analog of Avastin®, RPH-001. RPH-001 and Avastin® have similar physicochemical properties, pharmacokinetic profile and affinity to human vascular endothelial growth factor, similar toxicity and efficacy confirmed by preclinical study results.
Lead Sponsor
TRPHARM
INDUSTRY